Novo Signs $2 Billion Deal With United Labs for Obesity Drug
Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity drug, the Danish Ozempic maker’s latest move to refill its pipeline of experimental treatments.
Novo licenses Chinese biotech's obesity drug candidate for up to $2 billion
(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United Laboratories International's weight-loss drug candidate in a deal worth up to $2 billion.
Novo Nordisk Is Licensing a Chinese Weight-Loss Drug. Why the Stock Is Down.
Novo Nordisk said it had agreed to license a potential rival to its weight-loss drug Ozempic from a Chinese company. The Danish pharma company said it would pay $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the rights to UBT251,
Novo Nordisk Strikes $2B Deal for Obesity Drug
KEY TAKEAWAYS Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.
Novo Nordisk Strikes Up to $2 Billion Licensing Deal for Chinese Firm's Obesity, Diabetes Drug Candidate
Novo Nordisk (NVO) secured exclusive global rights to United Laboratories International's therapeutic candidate for obesity and type 2 diabetes in a licensing deal worth up to $2 billion. The product called UBT251 targets the receptors for glucagon-like peptide-1,
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The issuer is solely responsible for the content of this announcement.
TipRanks on MSN3d
United Laboratories’ Liraglutide Injection Gains NMPA Approval
The United Laboratories International Holdings ( ($HK:3933) ) has issued an update. The United Laboratories International Holdings Limited ...
The United Laboratories International Holdings Limited (OTCMKTS:ULIHF) Short Interest Update
The United Laboratories International Holdings Limited (OTCMKTS:ULIHF – Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 28th, ...
Seeking Alpha9mon
ULIHF The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.